VRCA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VR

Mkt Cap

$61.2M

Volume

112.49K

Next Earnings

November 13th

Loading chart

VR

VRCAVerrica Pharmaceuticals Inc. Common Stock

VRCA

Pay with—

Available Balance0.00

VR

Mkt Cap

$64.9M

Volume

112.49K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common WartsVerrica Pharmaceuticals announced the first patient dosing in a global Phase 3 clinical trial for YCANTH (VP-102) to treat common warts, a condition affecting approximately 22 million patients in the U.S. with no FDA-approved prescription therapies. The Phase 3 program is based on positive Phase 2 COVE-1 results showing 51% complete clearance of warts. Torii will fund approximately 90% of trial costs on a 50/50 cost-sharing basis, with Verrica's portion covered by future milestones and royalties from Japan.GlobeNewswire Inc. · Jan 7, 2026

Verrica Posts Profit in Fiscal Q2Verrica Pharmaceuticals reported strong Q2 2025 financial results, with non-GAAP EPS of $0.25 and GAAP revenue of $12.7 million, significantly exceeding analyst expectations. The company saw improved performance driven by YCANTH product sales and a major milestone payment from Torii Pharmaceutical.The Motley Fool · Aug 13, 2025

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology ConferenceVerrica Pharmaceuticals announced the acceptance of two abstracts featuring positive preliminary results from a Phase 2 study of its investigational therapy VP-315 for the treatment of basal cell carcinoma. The data showed promising safety, tolerability, and antitumor efficacy.GlobeNewswire Inc. · Oct 24, 2024

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial ResultsVerrica Pharmaceuticals reported Q2 2024 financial results, including $4.9M in YCANTH revenue and positive preliminary results from a Phase 2 study of VP-315 for basal cell carcinoma. The company also announced progress in its common warts program and expansion of YCANTH distribution.GlobeNewswire Inc. · Aug 14, 2024

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United StatesGlobeNewswire Inc. · Jul 1, 2024

Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsGlobal pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025GlobeNewswire Inc. · May 15, 2024

Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For TuesdayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Roth MKM cut the price target for Roblox Corporation (NYSE:RBLX) from $55 to $35. Roth MKM analyst Eric Handler downgraded the stock from Buy to Neutral. Roblox shares fell 1.6% to close at $30.96 on Monday. See how other analysts view this stock. Needham boosted the price target for Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) from $8 to $16. Needham analyst Serge Belanger maintained a Buy rating. Verrica Pharmaceuticals shares jumped 19.5% to close at $9.56 on Monday. See how other analysts view this stock. Baird cut Fortrea Holdings Inc. (NASDAQ:FTRE) price target from $45 to $36. Baird analyst Eric Coldwell upgraded the stock from Neutral to Outperform. Fortrea ...Full story available on Benzinga.comBenzinga · May 14, 2024

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesVerrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 29.63% and 41.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 13, 2024

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results– Reports YCANTH® revenue of $3.2M for first quarter of 2024 –GlobeNewswire Inc. · May 13, 2024

Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue EstimatesXeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 9, 2024

to start trading

VR

VRCAVerrica Pharmaceuticals Inc. Common Stock

VRCA

Pay with—

Available Balance0.00

Your PositionYou don't own any VRCA yet.

Related Tickers

Earnings